AVTX
Avalo Therapeutics Inc
13.60$
-6.9%
vs. previous close
Closing price · As of: Oct 6, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | 714.6% | 2.3% | 40.8% | -8.4% | 4.5% | 27.6% | 19.0% | 66.7% | -83.0% | 583.1% | |
| – | – | -614.6% | 97.7% | 59.2% | 108.4% | 95.5% | 72.4% | 81.0% | 33.3% | 183.0% | 100.0% | |
| – | – | 880.3% | 15.7% | 31.6% | 174.3% | 480.6% | 1,108.5% | 173.4% | 716.4% | 11,809.1% | 84,888.1% | |
| – | – | 614.3% | 28.6% | 58.3% | 150.0% | 260.0% | 426.1% | 114.3% | 533.6% | 3,730.6% | 38,016.9% | |
| – | – | 1,494.6% | 47.8% | 161.1% | 347.5% | 95.5% | 1,593.9% | 288.4% | 1,454.8% | 15,718.6% | 123,701.7% | |
| – | – | -1,394.6% | 49.9% | -214.5% | -239.1% | -402.3% | -1,521.6% | -207.4% | -1,421.6% | -15,535.6% | -123,601.7% | |
| – | – | 40.3% | 0.1% | 4.4% | 43.1% | 587.3% | 44.3% | 23.1% | 177.6% | 752.2% | – | |
| – | – | -1,428.5% | 49.7% | -218.7% | -236.9% | -1,002.8% | -1,566.2% | -230.6% | -1,638.8% | -7,939.9% | -132,362.7% | |
| – | – | 31.6% | 7.1% | -0.2% | 4.2% | -41.7% | -3.6% | 0.2% | 0.7% | 25.9% | 279.7% | |
| – | – | -1,428.5% | 42.7% | -218.5% | -238.1% | -947.9% | -1,563.1% | -230.8% | -1,639.5% | -7,965.8% | -132,642.4% | |
| – | – | -1,392.3% | 51.6% | -71.3% | -200.1% | -678.5% | -1,491.2% | -206.6% | -1,210.3% | -7,901.6% | -131,779.7% |
Data as of: October 6, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.